Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.85 |
| ▸ | AR | P10275 | 17/20 | 0.82 |
| ▸ | GABRP | O00591 | 1/20 | 0.82 |
| ▸ | GABRD | O14764 | 1/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.82 |
| ▸ | PGR | P06401 | 1/20 | 0.82 |
| ▸ | KLK3 | P07288 | 1/20 | 0.82 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.82 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.82 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.82 |
| ▸ | CNR1 | P21554 | 1/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.82 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.82 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.82 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.82 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.82 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.82 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.82 |
| ▸ | GABRE | P78334 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26276099 | 0.94 | ABCG2 (0.75) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL10020942 | 0.93 | ABCG2 (0.85) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL189635 | 0.92 | ABCG2 (1.00) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL29563592 | 0.91 | AR (0.82) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL19529497 | 0.91 | AR (0.82) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL189439 | 0.91 | AR (0.81) | ABCG2ARGABRPGABRDNR1I2 | |
| Enzalutamide SCHEMBL29352764 | 0.90 | AR (1.00) | ABCG2ARGABRPGABRDNR1I2 | |
| Enzalutamide SCHEMBL189749 | 0.90 | AR (1.00) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL21788386 | 0.90 | AR (0.87) | ABCG2ARGABRPGABRDNR1I2 | |
| SCHEMBL16182371 | 0.90 | ABCG2 (0.81) | ABCG2ARGABRPGABRDNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025108406-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR, AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| CN-120025333-A | Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof | 广东东阳光药业股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119684280-A | Targeting protein arginine methylation proximity-induced small molecule chimeric platform MeTAG and application thereof | 西安交通大学医学院第一附属医院 | 2025-03-25 | — | — | CN | disclosed |
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2024-10-24 | — | — | US | disclosed |
| EP-4426680-A1 | ANDROGEN RECEPTOR DEGRADERS FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND USE THEREOF | Autotac Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024103494-A1 | LOCALLY ACTING ANDROGEN RECEPTOR ANTAGONIST AND USE THEREOF | 南京思聚生物医药有限公司 | 2024-05-23 | — | — | WO | disclosed |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2013-07-25 | — | — | US | disclosed |
| EP-2538785-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| EP-2400847-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011106570-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106570-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | ABCG2 350/4885AR 9/4885GABRP 766/4885 |
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | ABCG2 350/4885AR 9/4885GABRP 766/4885 |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | BPHL, PTMS, DHPS | ABCG2 2560/4885AR 5/4885GABRP 3182/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | ABCG2 330/4885AR 5/4885GABRP 1113/4885 |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | ABCG2 1388/4885AR 266/4885GABRP 4093/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | ABCG2 531/4885AR 5/4885GABRP 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.